| Methods |
Randomisation technique not stated
Double‐blind, placebo controlled
No loss to FU |
| Participants |
Poland
15 male, 11 female
Mean age 67 years
Enrolment between 48 hours and 5 days
100% EEG and CSF pre‐entry diagnosis of CI |
| Interventions |
Rx: PGI2 (epoprostenol, Wellcome, UK, and Upjohn Co, USA), 5 x 6 hour consecutive 2.5 to 5 ng/kg/min iv infusions (depending on patients tolerance), separated by 6 hour intervals
Pl: solvent
Duration: 54 hours |
| Outcomes |
Death at 2 weeks
Neurological impairment assessed using modified Matthew score at baseline, after 6 and 54 hours, 2 weeks |
| Notes |
Ex: heart failure, hyperglycaemia, uraemia, hyperpyrexia, previous stroke
FU: 2 weeks
Further information unavailable since original data discarded |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
